Epithelial endothelial transition and endothelial mesenchymal transition

DOMENICO RIBATTI

ACCEPTED MANUSCRIPT

The International Journal of Developmental Biology publishes an “Accepted” manuscript format as a free service to authors in order to expedite the dissemination of scientific findings to the research community as soon as possible after acceptance following peer review and corresponding modification (where appropriate).

An “Accepted” manuscript is published online prior to copyediting, formatting for publication and author proofing, but is nonetheless, fully citable through its Digital Object Identifier (DOI). Nevertheless, this “Accepted” version is NOT the final version of the manuscript.

When the final version of this paper is published within a definitive issue of the journal with copyediting, full pagination, etc. the new final version will be accessible through the same doi and this "Accepted" version of the paper will disappear.
Epithelial-endothelial transition and endothelial--mesenchymal transition

Domenico Ribatti

Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School,
Bari, Italy

Correspondence to:

Prof. Domenico Ribatti
Department of Basic Medical Sciences, Neurosciences and Sensory Organs
University of Bari Medical School
Policlinico - Piazza G. Cesare, 11, 70124 Bari, Italy
Phone: + 39.080.5478326
E-mail: domenico.ribatti@uniba.it
Abstract. The movement of continuous sheets of epithelial cells occurs during embryonic development, tissue repair, and cancer. Common to cellular and molecular principles of collective cell migration, invading cancers seem to reactivate embryonic pathways and patterns of cell movement. Epithelial cells possess the capability to become mesenchymal cells in a process called epithelial mesenchymal transition (EMT), which has been extensively studied and described. The aim of this article is to summarizes the most recent literature data concerning less known epithelial-endothelial transition and endothelial-mesenchymal transition.

Keywords. Epithelial-mesenchymal transition; epithelial-endothelial transition; endothelial-mesenchymal transition; morphogenesis; tumor growth.
Introduction

The movement of continuous sheets of epithelial cells occurs during embryonic development, tissue repair, and cancer [Friedl and Gilmour, 2009]. The different strategies of epithelial cell migration are likely to be related to physiological differences between cell types and are influenced by the environment through which cells must migrate. Epithelial cells have a clear apico-basal polarity with cell–matrix adhesion at their basal side and cell–cell adhesion at their apical side, and when epithelial cells undergo collective migration, they maintain part of their epithelial characteristics. Collective migration is one of the hallmarks of embryonic morphogenesis, while collective invasion is prevalent in many cancer types. Common to cellular and molecular principles of collective cell migration, invading cancers seem to reactivate embryonic pathways and patterns of cell movement.

Epithelial cells possess the capability to become mesenchymal cells in a process called epithelial mesenchymal transition (EMT) [Ribatti, 2017]. During EMT, stable cell–cell junctions are disassembled, apico-basal polarity is lost, and migratory capabilities are enhanced. EMTs are classified in three types, including type 1, which occurs during embryonic development: type 2, which is associated with adult tissue repair; type 3, which is involved in cancer progression [Kalluri and Weinberg, 2009; Zeisberg and Neilson, 2009]. Cancers exhibit some degree of EMT during their progression, and epithelial tumors are the result of an EMT process, in which tumor cells lose their epithelial features, including cell adhesion and polarity, reorganize their cytoskeleton, and acquire a mesenchymal morphology and the ability to migrate.

Endothelial cell migration is essential to vasculogenesis and angiogenesis, and is directionally regulated by different stimuli, involving degradation of the extracellular matrix to enable progression of the migrating cells. It requires the activation of several signaling pathways that converge on cytoskeletal remodeling, and different regulatory mechanisms and factors controls this process, including include gradients of soluble factors, extracellular matrix–cell interaction and cell–
cell interaction. Three types of cells make up the new vasculature: tip cells, which migrate in response to gradients of vascular endothelial growth factor (VEGF), stalk cells, which proliferate and extend the vessels, and phalanx cells, which are quiescent and support the sprout [Ribatti and Crivellato, 2012]. The aim of this article is to summarize the most recent literature data concerning the study of epithelial/endothelial transition and endothelial/mesenchymal transition by means of different \textit{in vitro} and \textit{in vivo} models, including cellular models, such as the use of genetic lineage tracing technology enabling to follow endothelial cell lineage conversion \textit{in vivo}, murine models and patient bioptic specimens’ analysis.

\textbf{Epithelial/endothelial transition}

Epithelial endothelial transition (EET), a subtype of EMT, is a process of transformation of tumor epithelial cells in endothelial cells. Tumor cells lose their polarity and tight junctions, involving decreased expression of E-cadherin and occludin, and increased expression of vimentin, VE-cadherin, fibronectin, and vitronectin [Sun et al., 2016]. EET is involved also in kidney allograft fibrosis associated to tubular atrophy [Granata et al., 2020].

EET occurs during vasculogenic mimicry (VM), i.e., cancer cell-derived channels like blood vessels, acting as alternative source of nutrient and oxygen supply and involved in tumor growth and invasion. In 1999, Maniotis and coworkers described for the first time this process in human melanoma, showing trans-differentiation of melanoma cells, which results in the formation of a chimeric vasculature composed of melanoma and endothelial cells [Maniotis et al., 1999]. Since then, VM has been demonstrated in renal cell carcinoma, breast cancer, ovarian cancer, primary gallbladder cancer, esophageal squamous cell carcinoma, mesothelioma, alveolar rhabdomyosarcoma, and hepatocellular carcinoma [Cao and Qian, 2020].
During VM epithelial-derived tumor cells differentiate into cell types expressing some endothelial markers, including VE-cadherin and vimentin. VM formation is promoted by TGFβ and CXCL12/Stromal cell derived factor-1 (SDF-1) secreted by cancer associated fibroblasts (CAFs), which are involved in EET [Yang et al., 2016].

**Molecular pathways involved in EET**

Hypoxia induces the EET of cancer stem cells (CSCs) and EET is also associated to the promotion of VM. An EMT transcription factor Twist 1, is involved also for EET [Sun et al., 2011]. Under hypoxia, Twist1 translocate to the nucleus and bind to VE-cadherin promoter to induce EET and VM in hepatocellular carcinoma [Sun et al., 2010]. Similarly, hypoxia-associated Twist1 overexpression upregulates VE-cadherin in MDA-MB-231 triple negative breast cancer (TNBC) cells, and induces these cells to generate CSCs and promote VM in Matrigel [Zhang et al., 2014]. In hepatocellular carcinoma, the Bcl2/Twist1 complex leads to transcriptional activation of different genes that induce EET and VM [Sun et al., 2011]. Moreover, in hepatocellular carcinoma, overexpression of Twist1 under hypoxic conditions increased matrix metalloproteinases-2 and -9 (MMP-2 and MMP-9) expression and VM [Sun et al., 2011]. Also protease-activated receptor-1 (PAR-1) promotes EET through Twist1 in hepatocellular carcinoma by up-regulating Twist1 both in vitro and in vivo through thrombin binding [Xiao et al., 2018]. Overall, these data indicate that a significant correlation between the expression level of VM-related proteins, including VEGF receptor-1 and -2 (VEGFR-1 and VEGFR-2), vascular endothelial-cadherin, vimentin, MMP-2 and MMP-9, and protease activated receptor-1 (PAR-1), has been found in hepatocellular carcinoma bioptic specimens [Xiao et al., 2018].
**Endothelial/mesenchymal transition**

Endothelial cells may de-differentiate into mesenchymal stem-like cells (MSCs) and acquire the characteristics of multipotent cells [Medici and Kalluri, 2014]. This process has been defined as endothelial to mesenchymal transition (EndoMT). During EndoMT, endothelial cells lose endothelial markers and acquire mesenchymal markers (Table 1).

EndoMT takes place during embryogenesis [Timmermann et al., 2003], aorta development, pulmonary artery development, cardiogenesis and vasculogenesis [Arciniega et al., 1989; 2005].

During cardiogenesis, endothelial cells undergo EndoMT, invade the cardiac jelly, and generate the cardiac cushion (precursors of the semilunar valves) [Kovacic et al., 2012]. During the formation of heart valves, endocardial cells show morphological alterations, including cellular hypertrophy, lateralization of the Golgi apparatus and loss of cell polarity [Markwald and Fizharris, 1975]. During the formation of the endocardial cushion in the chick embryo, cardiac endothelial cells show phenotypic changes correlated with alpha smooth actin expression (αSMA) [Nakajima et al., 1997]. Epicardial cells also undergo EMT to give rise to smooth muscle cells, interstitial cardiac stromal cells and potentially a sub-population of endothelial cells [Kovacic et al., 2012]. EndoMT contributes to the vascular remodeling and neo-intimal formation that arises following vein graft transplantation into the arterial circulation [Cooley et al., 2014].

EndoMT is involved in different pathological conditions including pulmonary hypertension, transplant arteriopathy, vascular malformations, myocardial infarction, vascular calcification, fibrodysplasia ossificans progressive, cardiac, and renal fibrosis, and atherosclerosis (Table 2). Moreover, EndoMT is involved in different type of cancers (Table 3). Tumor-induced EndoMT is associated with the activation of pro-inflammatory pathways in endothelial cells (Nie et al., 2014). Endothelial cells undergoing tumor induced EndoMT express higher levels of the VEGG gene (Hog
et al., 2018). Moreover, EndoMT contributes to metastatic extravasation and intravasation (Dudley et al., 2012).

**Molecular pathways involved in EndoMT**

Several signaling pathways are involved in EndoMT, including Notch, transforming growth factor beta (TGFβ), WNT, fibroblast growth factor (FGF) and epidermal growth factor (EGF) [Man et al., 2018]. TGFβ is a potent activator of the EndoMT program in developmental and pathological settings [Arcinegas et al., 1992; Pardoli et al., 2017; Xiao et al., 2015; Mai et al., 2021]. Notch promotes TGFβ-mediated EndoMT in embryonic heart through the induction of Snail-1 expression and a down-regulation of VE-cadherin expression [Timmerman et al., 2003]. Induction of EndoMT through TGFβ involves a pathway leading to an increase of Snail-1 through convergence of Smad-dependent and Smad independent signaling [Medici et al., 2011]. TGF-β2 drives EndoMT through a Smad-dependent activation of the myocardin-related transcription factor-A (MRTF-A) (Mihira et al., 2012). Snail up-regulation is delayed following TGFβ activation of EndoMT in cultured endothelial cells [Sobierajska et al., 2020]. Smad independent pathways include MAPK/ERK/JNK [Medici et al., 2011; Heldin and Moustakas, 2011]. Snail is also required for TGFβ-induced EndoMT of embryonic stem cell-derived endothelial cells [Kokudo et al., 2008]. Snail acts as a transcription factor of EndoMT induced by Smad-dependent and PI3K/p38-dependent signaling pathways (Medici et al., 211). HGF/cMet signaling prevents TGFβ-1-induced EndoMT in cardiac fibrosis [Okayama et al., 2012; Wang et al., 2018].

FGF-2 inhibits EndoMT through miRNA-20a-mediated repression of TGFβ signaling [Correia et al., 2015]. Otherwise, FGF-2 promotes TGFβ-mediated EndoMT through regulation of let-7 miRNA
expression [Chen et al., 2012]. TNFα enhances TGFβ-induced EndoMT through TGFβ signal augmentation [Yoshimatsu et al., 2020].

During sprouting angiogenesis, an EndoMT is activated in endothelial cells to support the acquisition of mesenchymal features. VEGF and TGFβ may antagonize one another: exogenous VEGF treatment prevents TGFβ-induced EndoMT during cardiac fibrosis [Illigens et al., 2017]. Otherwise, human pulmonary valve progenitor cells exhibit EndoMT in response to VEGF-A and TGFβ-2 [Paruchuri et al., 2006]. Both Slug and Snail are involved in sprouting angiogenesis [Welch-Reardon et al., 2015]. Slug is the primary initiator of this process, whereas the induction of Snail occurs later.

Hypoxia is an inducer of EndoMT through the regulation of the expression of TGFβ-1, -2, and -3 [Caniggia et al., 2000; Hung et al., 2013]. Hypoxia inducible factor 1 alpha (HIF-1α) induces EndoMT of human coronary endothelial cells and Snail is a direct target of HIF-1α [Xu et al., 2015]. Hypoxia induces the expression of Endo-MT-associated transcription factors Snail and Slug [Zhang et al., 2003].

**Therapeutic approaches**

As CSCs and EET promote VM in malignant tumors, doxycycline as an inhibitor of EMT and VM in hepatocellular carcinoma, prevents also EET through methylation of the E-cadherin gene and down-regulation of vimentin and VE-cadherin [Meng et al., 2014].

A conjugate of Temozolomide and perillyl alcohol inhibits EndoMT and reverts the mesenchymal phenotype of tumor associated brain endothelial cells in glioblastoma [Marin-Ramos et al., 2019]. Resistance to cisplatin and Getifinib in lung tumor spheroid model is reduced when EndoMT in endothelial cells is reversed, implying EndoMT as a resistance factor [Kim et al., 2019]. Several drugs with anti-EndoMT properties have been approved for treatment of idiopathic pulmonary fibrosis, such as Nintedanib, a tyrosine kinase inhibitor of PDGF, FGF, and VEGF [Tsutsumi et al., 2019] and
diabetic kidney disease, such as Losartan, an inhibitor of TGFβ-Smad 2-3 pathway [Yao et al., 2018]. EndoMT in systemic sclerosis induced by endothelin-1 (ET-1) and TGFβ may be blocked by Macitentan, a dual ET-1 receptor antagonist (Cipriani et al., 2015). Vildagliptin, an anti-diabetic drug, ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting EndoMT (Suzuki et al., 2017). Calcitriol, an active form of vitamin D3, reduces TGFβ-Smad2-mediated EndoMT and fibroblast to myofibroblast transition (Tsai et al., 2019).

**Concluding remarks**

EET is involved in transformation of tumor epithelial cells in endothelial cells and occurs during VM, i.e., cancer cell-derived channels like blood vessels, acting as alternative source of nutrient and oxygen supply and involved in tumor growth and invasion. Otherwise, EndoMT is involved in embryogenesis, tumor development, and contributes to resistance to cancer treatment. For example, in glioblastoma multiforme, chemoresistance is related to c-met-mediated EndoMT (Huang et al., 2016).

EET and EndoMT are controlled by complex signaling pathways. Different evidence suggests the existence of a complex signaling network involving TGFβ, Wnt/β-catenin and Notch pathways involved in the control of EndoMT. In this context, modulation of both EET EndoMT may contribute to counteract tumor progression and the molecular regulators of these two processes are potential targets and prognostic indicators. Single cell analysis of tumor cells may allow to analyze the different pathways involved in EET and EndoMT and to discriminate between the molecular alterations underlying tumor progression and the different response to therapeutic agents.
References

E. Arciniegas, M. Servin, C. Argüello, M. Mota, Development of the aorta in the chick embryo: structural and ultrastructural study, Atherosclerosis 76 (1989) 219-235.

E. Arciniegas, A.B. Sutton, T.D. Allen, A.M. Schor, Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro, Journal of Cell Science 103 (1992) 521-529.

E. Arciniegas, C.Y. Neves, L.M. Carrillo, E.A. Zambrano, R. Ramírez, Endothelial-Mesenchymal Transition Occurs during Embryonic Pulmonary Artery Development, Endothelium 12 (2005) 193-200.

E. Arciniegas, M.G. Frid, I.S. Douglas, K.R. Stenmark, Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension, American Journal of Physiology-Lung Cellular and Molecular Physiology 293 (2007) L1-L8.

I. Caniggia, H. Mostachfi, J. Winter, M. Gassmann, S.J. Lye, M. Kuliszewski, M. Post, Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFβ3, Journal of Clinical Investigation 105 (2000) 577-587.

Y. Cao, B. Feng, S. Chen, Y. Chu, S. Chakrabarti, Mechanisms of Endothelial to Mesenchymal Transition in the Retina in Diabetes, Investigative Ophthalmology & Visual Science 55 (2014) 7321.

Y. Cao, C.-N. Qian, Vasculogenic mimicry, Tumor Vascularization, Elsevier, 2020, pp. 89-100.

P.-Y. Chen, L. Qin, C. Barnes, K. Charisse, T. Yi, X. Zhang, R. Ali, Pedro P. Medina, J. Yu, Frank J. Slack, Daniel G. Anderson, V. Kotelianski, F. Wang, G. Tellides, M. Simons, FGF Regulates TGF-β Signaling and Endothelial-to-Mesenchymal Transition via Control of let-7 miRNA Expression, Cell Reports 2 (2012) 1684-1696.
Choi, S. H., Kim, A. R., Nam, J. K., Kim, J. M., Kim, J. Y., Seo, H. R., et al. (2018). Tumour-vasculature development via endothelial-to-mesenchymal transition after radiotherapy controls CD44v6(+) cancer cell and macrophage polarization. Nat. Commun. 9:5108. doi: 10.1038/s41467-018-07470-w

Cipriani, P. et al. The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-beta and may be blocked by macitentan, a dual endothelin-1 receptor antagonist. J. Rheumatol. 42, 1808–1816 (2015)

B.C. Cooley, J. Nevado, J. Mellad, D. Yang, C. St. Hilaire, A. Negro, F. Fang, G. Chen, H. San, A.D. Walts, R.L. Schwartzbeck, B. Taylor, J.D. Lanzer, A. Wragg, A. Elagha, L.E. Beltran, C. Berry, R. Feil, R. Virmani, E. Ladich, J.C. Kovacic, M. Boehm, TGF-β Signaling Mediates Endothelial-to-Mesenchymal Transition (EndMT) During Vein Graft Remodeling, Science Translational Medicine 6 (2014).

A.C.P. Correia, J.-R.A.J. Moonen, M.G.L. Brinker, G. Krenning, FGF-2 inhibits Endothelial-Mesenchymal Transition through microRNA-20a-mediated repression of canonical TGF-β Signaling, Journal of Cell Science (2015).

Dudley, A. C. Tumor endothelial cells. Cold Spring Harb. Perspect. Med. 2, a006536 (2012)

C.-S. Fan, W.-S. Chen, L.-L. Chen, C.-C. Chen, Y.-T. Hsu, K.V. Chua, H.-D. Wang, T.-S. Huang, Osteopontin-integrin engagement induces HIF-1α–TCF12-mediated endothelial-mesenchymal transition to exacerbate colorectal cancer, Oncotarget 9 (2017) 4998-5015.

Fan, C. S., Chen, W. S., Chen, L. L., Chen, C. C., Hsu, Y. T., Chua, K. V., et al. (2018). Osteopontin-integrin engagement induces HIF-1alphaTCF12-mediated endothelial-mesenchymal transition to exacerbate colorectal cancer. Oncotarget 9, 4998–5015. doi: 10.18632/oncotarget.23578

Fan, C. S., Chen, L. L., Hsu, T. A., Chen, C. C., Chua, K. V., Li, C. P., et al. (2019). Endothelial-mesenchymal transition harnesses HSP90alpha-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma. J. Hematol. Oncol. 12:138. doi: 10.1186/s13045-019-0826-2

P. Friedl, D. Gilmour, Collective cell migration in morphogenesis, regeneration and cancer, Nature Reviews Molecular Cell Biology 10 (2009) 445-457.
S. Granata, C. Benedetti, G. Gambaro, G. Zaza, Kidney allograft fibrosis: what we learned from latest translational research studies, Journal of Nephrology 33 (2020) 1201-1211.

N. Hashimoto, S.H. Phan, K. Imaizumi, M. Matsuo, H. Nakashima, T. Kawabe, K. Shimokata, Y. Hasegawa, Endothelial–Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis, American Journal of Respiratory Cell and Molecular Biology 43 (2010) 161-172.

C.-H. Heldin, A. Moustakas, Role of Smads in TGFβ signaling, Cell and Tissue Research 347 (2011) 21-36.

Hong, L. et al. EndMT: a promising and controversial field. Eur. J. Cell Biol. 97, 493–500 (2018)

R.K. Hopper, J.-R.A.J. Moonen, I. Diebold, A. Cao, C.J. Rhodes, N.F. Tojais, J.K. Hennigs, M. Gu, L. Wang, M. Rabinovitch, In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug, Circulation 133 (2016) 1783-1794.

Huang, M., Liu, T., Ma, P., Mitteer, R. A. Jr., and Zhang, Z. (2016). c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. J. Clin. Invest. 126, 1801–1814. doi: 10.1172/JCI84876

Huang, M., Zhang, D., Wu, J. Y., Xing, K., Yeo, E., Li, C., et al. (2020). Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. Sci. Transl. Med. 12:532. doi: 10.1126/scitranslmed.aay7522

S.-P. Hung, M.-H. Yang, K.-F. Tseng, O.K. Lee, Hypoxia-Induced Secretion of TGF-β1 in Mesenchymal Stem Cell Promotes Breast Cancer Cell Progression, Cell Transplantation 22 (2013) 1869-1882.

B.M.W. Illigens, A. Casar Berazaluce, D. Poutias, R. Gasser, P.J. del Nido, I. Friehs, Vascular Endothelial Growth Factor Prevents Endothelial-to-Mesenchymal Transition in Hypertrophy, The Annals of Thoracic Surgery 104 (2017) 932-939.

R. Kalluri, R.A. Weinberg, The basics of epithelial-mesenchymal transition, Journal of Clinical Investigation 119 (2009) 1420-1428.
S.-H. Kim, Y. Song, H.R. Seo, GSK-3β regulates the endothelial-to-mesenchymal transition via reciprocal crosstalk between NSCLC cells and HUVECs in multicellular tumor spheroid models, Journal of Experimental & Clinical Cancer Research 38 (2019).

T. Kokudo, Y. Suzuki, Y. Yoshimatsu, T. Yamazaki, T. Watabe, K. Miyazono, Snail is required for TGFβ-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells, Journal of Cell Science 121 (2008) 3317-3324.

J.C. Kovacic, N. Mercader, M. Torres, M. Boehm, V. Fuster, Epithelial-to-Mesenchymal and Endothelial-to-Mesenchymal Transition, Circulation 125 (2012) 1795-1808.

J. Li, X. Qu, J.F. Bertram, Endothelial-Myofibroblast Transition Contributes to the Early Development of Diabetic Renal Interstitial Fibrosis in Streptozotocin-Induced Diabetic Mice, The American Journal of Pathology 175 (2009) 1380-1388.

Liu, T., Ma, W., Xu, H., Huang, M., Zhang, D., He, Z., et al. (2018). PDGF-mediated mesenchymal transformation renders endothelial resistance to antiVEGF treatment in glioblastoma. Nat. Commun. 9:3439. doi: 10.1038/s41467-018-05982-z

W. Ma, Y. Wang, R. Zhang, F. Yang, D. Zhang, M. Huang, L. Zhang, J.F. Dorsey, Z.A. Binder, D.M. O’Rourke, J.A. Fraietta, Y. Gong, Y. Fan, Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma, Nature Cancer 2 (2021) 83-97.

S. Man, G. Sanchez Duffhues, P. ten Dijke, D. Baker, The therapeutic potential of targeting the endothelial-to-mesenchymal transition, Angiogenesis 22 (2018) 3-13.

M. Manetti, E. Romano, I. Rosa, S. Guiducci, S. Bellando-Randone, A. De Paulis, L. Ibba-Manneschi, M. Matucci-Cerinic, Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis, Annals of the Rheumatic Diseases 76 (2017) 924-934.
A.J. Maniotis, R. Folberg, A. Hess, E.A. Seftor, L.M.G. Gardner, J. Pe'er, J.M. Trent, P.S. Meltzer, M.J.C. Hendrix, Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry, The American Journal of Pathology 155 (1999) 739-752.

N.I. Marín-Ramos, N. Jhaveri, T.Z. Thein, R.A. Fayngor, T.C. Chen, F.M. Hofman, NEO212, a conjugate of temozolomide and perillyl alcohol, blocks the endothelial-to-mesenchymal transition in tumor-associated brain endothelial cells in glioblastoma, Cancer Letters 442 (2019) 170-180.

R.R. Markwald, T.P. Fitzharris, W.N.A. Smith, Structural analysis of endocardial cytodifferentiation, Developmental Biology 42 (1975) 160-180.

D. Medici, S. Potenta, R. Kalluri, Transforming growth factor-β2 promotes Snail-mediated endothelial–mesenchymal transition through convergence of Smad-dependent and Smad-independent signalling, Biochemical Journal 437 (2011) 515-520.

D. Medici, R. Kalluri, Endothelial–mesenchymal transition and its contribution to the emergence of stem cell phenotype, Seminars in Cancer Biology 22 (2012) 379-384.

F.A. Mendoza, S. Piera-Velazquez, J.L. Farber, C. Feghali-Bostwick, S.A. Jiménez, Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease, Arthritis & Rheumatology 68 (2015) 210-217.

J. Meng, B. Sun, X. Zhao, D. Zhang, X. Zhao, Q. Gu, X. Dong, N. Zhao, P. Liu, Y. Liu, Doxycycline as an Inhibitor of the Epithelial-to-Mesenchymal Transition and Vasculogenic Mimicry in Hepatocellular Carcinoma, Molecular Cancer Therapeutics 13 (2014) 3107-3122.

Mihira, H., Suzuki, H. I., Akatsu, Y., Yoshimatsu, Y., Igarashi, T., Miyazono, K., et al. (2012). TGF-beta-induced mesenchymal transition of MS-1 endothelial cells requires Smad-dependent cooperative activation of Rho signals and MRTF-A. J. Biochem. 151, 145–156. doi: 10.1093/jb/mvr121
E. Mintet, E. Rannou, V. Buard, G. West, O. Guipaud, G. Tarlet, J.-C. Sabourin, M. Benderitter, C. Fiocchi, F. Milliat, A. François, Identification of Endothelial-to-Mesenchymal Transition as a Potential Participant in Radiation Proctitis, The American Journal of Pathology 185 (2015) 2550-2562.

Y. Nakajima, V. Mironov, T. Yamagishi, H. Nakamura, R.R. Markwald, Expression of smooth muscle alpha-actin in mesenchymal cells during formation of avian endocardial cushion tissue: a role for transforming growth factor beta3, Dev Dyn 209 (1997) 296-309.

Nie, L., Lyros, O., Medda, R., Jovanovic, N., Schmidt, J. L., Otterson, M. F., et al. Endothelial-mesenchymal transition in normal human esophageal endothelial cells cocultured with esophageal adenocarcinoma cells: role of IL1beta and TGF-beta2. Am J Physiol Cell Physiol 307 (2014) C859–C877.

K. Okayama, J. Azuma, N. Dosaka, K. Iekushi, F. Sanada, H. Kusunoki, M. Iwabayashi, H. Rakugi, Y. Taniyama, R. Morishita, Hepatocyte Growth Factor Reduces Cardiac Fibrosis by Inhibiting Endothelial-Mesenchymal Transition, Hypertension 59 (2012) 958-965.

E. Pardali, G. Sanchez-Duffhues, M. Gomez-Puerto, P. ten Dijke, TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases, International Journal of Molecular Sciences 18 (2017) 2157.

S. Paruchuri, J.-H. Yang, E. Aikawa, J.M. Melero-Martin, Z.A. Khan, S. Loukogeorgakis, F.J. Schoen, J. Bischoff, Human Pulmonary Valve Progenitor Cells Exhibit Endothelial/Mesenchymal Plasticity in Response to Vascular Endothelial Growth Factor-A and Transforming Growth Factor-β 2, Circulation Research 99 (2006) 861-869.

D. Ribatti, E. Crivellato, “Sprouting angiogenesis”, a reappraisal, Developmental Biology 372 (2012) 157-165.

D. Ribatti, Epithelial-mesenchymal transition in morphogenesis, cancer progression and angiogenesis, Experimental Cell Research 353 (2017) 1-5.
K. Sobierajska, W.M. Ciszewski, E. Macierzynska-Piotrowska, W. Klopacka, P. Przygodzka, M. Karakula, K. Pestka, M.E. Wawro, J. Niewiarowska, The New Model of Snail Expression Regulation: The Role of MRTFs in Fast and Slow Endothelial–Mesenchymal Transition, International Journal of Molecular Sciences 21 (2020) 5875.

C. Souilhol, M.C. Harmsen, P.C. Evans, G. Krenning, Endothelial–mesenchymal transition in atherosclerosis, Cardiovascular Research 114 (2018) 565-577.

B. Sun, D. Zhang, N. Zhao, X. Zhao, Epithelial-to-endothelial transition and cancer stem cells: two cornerstones of vasculogenic mimicry in malignant tumors, Oncotarget 8 (2016) 30502-30510.

Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, et al.. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology 51 (2010) 545-556.

T. Sun, B.-c. Sun, X.-l. Zhao, N. Zhao, X.-y. Dong, N. Che, Z. Yao, Y.-m. Ma, Q. Gu, W.-k. Zong, Z.-y. Liu, Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: A study of hepatocellular carcinoma, Hepatology 54 (2011) 1690-1706.

Suzuki, T, Tada Y, Gladson R, Nishimura I, Shimomura I, Karasawa S et al. Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-tomesenchymal transition. Respir Res 18 (2017) 177.

L.A. Timmerman, J. Grego-Bessa, A. Raya, E. Bertrán, J.M. Pérez-Pomares, J. Díez, S. Aranda, S. Palomo, F. McCormick, J.C. Izpisúa-Belmonte, J.L. de la Pompa, Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation, Genes & Development 18 (2003) 99-115.

L. Tombor, D. John, S.F. Glaser, G. Luxan, E. Forte, M. Furtado, N. Rosenthal, Y. Manavski, A. Fischer, M. Muhly-Reinholz, M. Looso, T. Acker, R. Harvey, A. Abplanalp, S. Dimmeler, Single cell sequencing reveals endothelial plasticity with transient mesenchymal activation after myocardial infarction, European Heart Journal 41 (2020).
Tsai, T. H. et al. Liraglutide inhibits endothelial-to-mesenchymal transition and attenuates neointima formation after endovascular injury in streptozotocin-induced diabetic mice. Cells 8, 589 (2019).

T. Tsutsumi, T. Nagaoka, T. Yoshida, L. Wang, S. Kuriyama, Y. Suzuki, Y. Nagata, N. Harada, Y. Kodama, F. Takahashi, Y. Morio, K. Takahashi, Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation, PLOS ONE 14 (2019) e0214697.

R.M. Tuder, B. Groves, D.B. Badesch, N.F. Voelkel, Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension, Am J Pathol 144 (1994) 275-285.

Z. Wang, S. Fei, C. Suo, Z. Han, J. Tao, Z. Xu, C. Zhao, R. Tan, M. Gu, Antifibrotic Effects of Hepatocyte Growth Factor on Endothelial-to-Mesenchymal Transition via Transforming Growth Factor-Beta1 (TGF-β1)/Smad and Akt/mTOR/P70S6K Signaling Pathways, Annals of Transplantation 23 (2018) 1-10.

Wawro, M. E., Chojnacka, K., Wieczorek-Szukala, K., Sobierajska, K., and Niewiarowska, J. (2018). Invasive colon cancer cells induce transdifferentiation of endothelium to cancer-associated fibroblasts through microtubules enriched in tubulin-beta3. Int. J. Mol. Sci. 20:53. doi: 10.3390/ijms20010053

K.M. Welch-Reardon, N. Wu, C.C.W. Hughes, A Role for Partial Endothelial–Mesenchymal Transitions in Angiogenesis?, Arteriosclerosis, Thrombosis, and Vascular Biology 35 (2015) 303-308.

B. Widyantoro, N. Emoto, K. Nakayama, D.W. Anggrahini, S. Adiarto, N. Iwasa, K. Yagi, K. Miyagawa, Y. Rikitake, T. Suzuki, Y.Y. Kisanuki, M. Yanagisawa, K.-i. Hirata, Endothelial Cell–Derived Endothelin-1 Promotes Cardiac Fibrosis in Diabetic Hearts Through Stimulation of Endothelial-to-Mesenchymal Transition, Circulation 121 (2010) 2407-2418.
S. Xavier, R. Vasko, K. Matsumoto, J.A. Zullo, R. Chen, J. Maizel, P.N. Chander, M.S. Goligorsky, Curtailing Endothelial TGF-β Signaling Is Sufficient to Reduce Endothelial-Mesenchymal Transition and Fibrosis in CKD, Journal of the American Society of Nephrology 26 (2014) 817-829.

L. Xiao, D.J. Kim, C.L. Davis, J.V. McCann, J.M. Dunleavey, A.K. Vanderlinden, N. Xu, S.G. Pattenden, S.V. Frye, X. Xu, M. Onaitis, E. Monaghan-Benson, K. Burridge, A.C. Dudley, Tumor Endothelial Cells with Distinct Patterns of TGFβ-Driven Endothelial-to-Mesenchymal Transition, Cancer Research 75 (2015) 1244-1254.

T. Xiao, Q. Zhang, S. Zong, W.-l. Zhong, Y. Qin, Z. Bi, S. Chen, H.-j. Liu, J.-j. Wei, B.-j. Zhou, L.-m. Wang, H.-g. Zhou, Y.-r. Liu, T. Sun, C. Yang, Protease-activated receptor-1 (PAR1) promotes epithelial-endothelial transition through Twist1 in hepatocellular carcinoma, Journal of Experimental & Clinical Cancer Research 37 (2018).

X. Xu, X. Tan, B. Tampe, E. Sanchez, M. Zeisberg, E.M. Zeisberg, Snail Is a Direct Target of Hypoxia-inducible Factor 1α (HIF1α) in Hypoxia-induced Endothelial to Mesenchymal Transition of Human Coronary Endothelial Cells, Journal of Biological Chemistry 290 (2015) 16653-16664.

Yamada, N. O., Heishima, K., Akao, Y., and Senda, T. (2019). Extracellular vesicles containing microRNA-92a-3p facilitate partial endothelial-mesenchymal transition and angiogenesis in endothelial cells. Int. J. Mol. Sci. 20:406. doi: 10.3390/ijms20184406

J. Yang, Y. Lu, Y.-Y. Lin, Z.-Y. Zheng, J.-H. Fang, S. He, S.-M. Zhuang, Vascular mimicry formation is promoted by paracrine TGF-β and SDF1 of cancer-associated fibroblasts and inhibited by miR-101 in hepatocellular carcinoma, Cancer Letters 383 (2016) 18-27.

Y. Yao, Y. Li, X. Zeng, Z. Ye, X. Li, L. Zhang, Losartan Alleviates Renal Fibrosis and Inhibits Endothelial-to-Mesenchymal Transition (EMT) Under High-Fat Diet-Induced Hyperglycemia, Frontiers in Pharmacology 9 (2018).
Y. Yoshimatsu, I. Wakabayashi, S. Kimuro, N. Takahashi, K. Takahashi, M. Kobayashi, N. Maishi, K.A. Podyma-Inoue, K. Hida, K. Miyazono, T. Watabe, TNF-α enhances TGF-β-induced endothelial-to-mesenchymal transition via TGF-β signal augmentation, Cancer Science 111 (2020) 2385-2399.

E.M. Zeisberg, O. Tarnavski, M. Zeisberg, A.L. Dorfman, J.R. McMullen, E. Gustafsson, A. Chandraker, X. Yuan, W.T. Pu, A.B. Roberts, E.G. Neilson, M.H. Sayegh, S. Izumo, R. Kalluri, Endothelial-to-mesenchymal transition contributes to cardiac fibrosis, Nature Medicine 13 (2007 a) 952-961.

E.M. Zeisberg, S. Potenta, L. Xie, M. Zeisberg, R. Kalluri, Discovery of Endothelial to Mesenchymal Transition as a Source for Carcinoma-Associated Fibroblasts, Cancer Research 67 (2007 b) 10123-10128.

M. Zeisberg, E.G. Neilson, Biomarkers for epithelial-mesenchymal transitions, Journal of Clinical Investigation 119 (2009) 1429-1437.

E.M. Zeisberg, S.E. Potenta, H. Sugimoto, M. Zeisberg, R. Kalluri, Fibroblasts in Kidney Fibrosis Emerge via Endothelial-to-Mesenchymal Transition, Journal of the American Society of Nephrology 19 (2008) 2282-2287.

H. Zhang, H.O. Akman, E.L.P. Smith, J. Zhao, J.E. Murphy-Ullrich, O.A. Batuman, Cellular response to hypoxia involves signaling via Smad proteins, Blood 101 (2003) 2253-2260.

D. Zhang, B. Sun, X. Zhao, Y. Ma, R. Ji, Q. Gu, X. Dong, J. Li, F. Liu, X. Jia, X. Leng, C. Zhang, R. Sun, J. Chi, Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer, Molecular Cancer 13 (2014).
| Loss of endothelial markers and acquisition of mesenchymal markers during EndoMT |
|---------------------------------|---------------------------------|
| **Endothelial markers**        | **Mesenchymal markers**        |
| CD31                           | N-cadherin                     |
| Platelet endothelial cell adhesion molecule-1 (PECAM-1) | Fibroblast specific protein-1 (FSP-1) |
| Tie-2                          | Alpha smooth muscle actin (αSMA) |
| Vascular endothelial (VE)-cadherin | Types I/III collagen           |
Table 2.

| Pathological conditions in which EndMT is involved | References |
|---------------------------------------------------|------------|
| Pulmonary arterial hypertension                    | Arcinegas et al., 2007; Hopper et al., 2016; Tuder et al., 1994 |
| Atherosclerosis                                    | Souilhol et al., 2018 |
| Cardiac fibrosis                                  | Widyantoro et al., 2010; Zeisberg et al., 2007a |
| Dermal fibrosis                                   | Manetti et al., 2017 |
| Radiation-induced rectal fibrosis                 | Mintet et al., 2015 |
| Myocardial infarction                             | Tombor et al., 2020 |
| Pulmonary fibrosis                                | Hashimoto et al., 2010 |
| Renal fibrosis                                    | Li et al., 2009; Xavier et al., 2014; Zeisberg et al., 2008 |
| Cancer                                            | Fan et al., 2017; Zeisberg et al., 2007b |
| Systemic sclerosis-associated interstitial lung disease | Mendoza et al., 2015 |
| Diabetes mellitus                                 | Li et al., 2009; Cao et al., 2014 |
| Different types of cancers in which EndoMT is involved | References |
|------------------------------------------------------|------------|
| Melanoma                                             | Zeisberg et al. 2007 b |
| Colorectal cancer                                    | Fan et al., 2018; Yamada et al., 2019; Wawro et al., 2018 |
| Pancreatic cancer                                    | Fan et al., 2019 |
| Lung cancer                                          | Choi et al., 2018; Kim et al., 2019 |
| Glioblastoma                                         | Huang et al., 2016, 2020; Liu et al., 2018 |
| Esophageal cancer                                    | Nie et al., 2014 |